LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 7 of 15: Mean cell count and mean growth rate across all replicates. - Dataset (ID:20243)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Mean Relative Cell Count | Standard Error of the Mean for Relative Cell Count | Mean Relative Growth Rate | Standard Error of the Mean for Relative Growth Rate |
|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP5 | 0.1923 | 0.0122 | -0.3484 | 0.0982 |
| SK-BR-3 | GSK1059615 | 10.0 | uM | LJP6 | 0.1916 | 0.0191 | -0.3465 | 0.0790 |
| SK-BR-3 | GSK1904529A | 10.0 | uM | LJP6 | 1.0116 | 0.0038 | 1.0190 | 0.0057 |
| SK-BR-3 | Omipalisib | 10.0 | uM | LJP6 | 0.1786 | 0.0263 | -0.3736 | 0.1221 |
| SK-BR-3 | GSK 690693 | 10.0 | uM | LJP5 | 0.7868 | 0.0385 | 0.6500 | 0.0477 |
| SK-BR-3 | GW843682X | 10.0 | uM | LJP6 | 0.4169 | 0.1025 | 0.0183 | 0.2141 |
| SK-BR-3 | HG-5-113-01 | 10.0 | uM | LJP5 | 0.3190 | 0.0160 | -0.1350 | 0.0717 |
| SK-BR-3 | HG-5-88-01 | 10.0 | uM | LJP6 | 0.4701 | 0.0137 | 0.1142 | 0.0730 |
| SK-BR-3 | Imatinib | 10.0 | uM | LJP6 | 0.9806 | 0.0192 | 0.9640 | 0.0347 |
| SK-BR-3 | JNK-9L | 10.0 | uM | LJP6 | 0.2988 | 0.0136 | -0.1685 | 0.0714 |
| SK-BR-3 | JW-7-24-1 | 10.0 | uM | LJP6 | 0.2851 | 0.0037 | -0.1921 | 0.0749 |
| SK-BR-3 | Lapatinib | 10.0 | uM | LJP6 | 0.4676 | 0.0234 | 0.1172 | 0.0138 |
| SK-BR-3 | LDN-193189 | 10.0 | uM | LJP5 | 0.1497 | 0.0149 | -0.4171 | 0.0861 |
| SK-BR-3 | Linifanib | 10.0 | uM | LJP6 | 0.5215 | 0.0162 | 0.2048 | 0.0320 |
| SK-BR-3 | Linsitinib | 10.0 | uM | LJP5 | 0.7146 | 0.0220 | 0.5251 | 0.0406 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP5 | 0.0937 | 0.0431 | -0.5069 | 0.0874 |
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 0.0754 | 0.0369 | -0.5397 | 0.1011 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 0.3630 | 0.0320 | -0.0556 | 0.0097 |
| SK-BR-3 | Neratinib | 10.0 | uM | LJP5 | 0.2851 | 0.0217 | -0.1960 | 0.1068 |
| SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 0.5134 | 0.0157 | 0.1899 | 0.0468 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 0.4223 | 0.1311 | 0.0576 | 0.1890 |
| SK-BR-3 | NU7441 | 10.0 | uM | LJP5 | 0.5056 | 0.0554 | 0.1865 | 0.0509 |
| SK-BR-3 | Dactolisib | 10.0 | uM | LJP5 | 0.4127 | 0.0107 | 0.0213 | 0.0592 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 0.2827 | 0.0515 | -0.1858 | 0.0266 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 0.6833 | 0.0115 | 0.4737 | 0.0222 |